Corcept Therapeutics (CORT) Revenue (2012 - 2026)

Corcept Therapeutics has disclosed Revenue across 15 years of filings, most recently posting $164.9 million for Q1 2026.

• Revenue for Q1 2026 came in at $164.9 million, up 4.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $769.1 million (up 12.2% YoY), and the FY2025 annual result was $761.4 million, up 12.79% from the prior year.
• Revenue came in at $164.9 million for Q1 2026 at Corcept Therapeutics, down from $202.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $207.6 million in Q3 2025 to a low of $93.7 million in Q1 2022.
• The 5-year median for Revenue is $146.8 million (2024), against an average of $146.2 million.
• Across the five-year window, Revenue climbed 4.28% in 2022 and jumped 47.69% in 2024, its largest moves.
• Corcept Therapeutics' Revenue stood at $103.1 million in 2022, then surged by 31.39% to $135.4 million in 2023, then jumped by 34.33% to $181.9 million in 2024, then gained by 11.12% to $202.1 million in 2025, then dropped by 18.42% to $164.9 million in 2026.
• The last three Revenue figures came in at $164.9 million (Q1 2026), $202.1 million (Q4 2025), and $207.6 million (Q3 2025), per Business Quant data.